	Substitute for	form 1449B/PTO			Complete if Known			
	INIEGE	DIATION D	ISCI	OSLIDE	Application Number			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	11-07-07		
	SIAII	EIVIEIVI DI	AFF	LICANI	First Named Inventor	Lars Michael Larsen		
	(U	se as many sheets a	s neces	ssarv)	Art Unit	1627		
	,,-				Examiner Name	Fay, 2.		
	Sheet	1	of	1	Attorney Docket Number	Larsen=5		

		NON PATENT LITERATURE DOCUMENTS						
Examiner nitial *	Cite No. <sup>1</sup>							
	1	Arden. The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br J Opthtalmol 85, 366-370 (2001)						
The second secon	2	Bernstein et al. Mechanism of action of aromatic amines that short-circuit the visual cycle. Biochemistry 25, 3370-3377 (1986)	E					
	3	Bershad. Developments in topical retinoid therapy for acne. Seminars in Cutaneous Medicine and Surgery, vol. 20, no. 3, 154-161 (2001)						
nertale nas valuentais e renere Prenins e Visita	4	Drasdo et al. Effect of drakness on inner retinal hypoxia in diabetes. The Lancet, 359, 2251-2253 (2002)						
	5	Kondo. Night blindness caused by 13-cis retinoic acid (Accutane). Journal of the Eye, 19(11), 1459-1460 (2002)						
	6	Zouboulis. Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol 14, 303-315 (2001)						
and the second								
	ad and a decision of the same							
n.a-mailleanneach earst ab a rain, de 18 d	00.00P-0-000000000000000000000000000000							
romanendismens karh-kent blikke hit dar in meldelember								
	niner ature	Date Considered						

Examine	Date	
Signature	Considered	
		L.

considered. Include copy of this form with next communication to applicant.